---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-162715"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:06:53.476754+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics director Ujwala Mahatme resigns; annual meeting elects all eight nominees

## Summary
- Director Ujwala Mahatme resigned effective June 12, 2024, to focus on professional commitments; no disagreement with company.
- At June 14 annual meeting, all eight director nominees elected with large majorities (e.g., Robert W. Duggan received 620.6M votes).
- Stockholders ratified PwC as independent auditor for FY 2024 with 639.3M votes for and 39.8K against.
- Non-binding advisory vote on executive compensation passed with 604.2M for, 15.9M against, and 18.9M broker non-votes.

## SEC filing metadata
- accession: 0001193125-24-162715
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/0001193125-24-162715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/d786440d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-162715
- JSON: https://secwatch.observer/filing/0001193125-24-162715.json
- Plain text: https://secwatch.observer/filing/0001193125-24-162715.txt

## Key facts
- Executive change
  Ujwala Mahatme resigned as Director at Summit Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the “Company”) that she was resigning from her role as a member of the Board of Directors (the “Board”) of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/0001193125-24-162715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.